Paul E. Oberstein

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Andrew D. Rhim, Paul E. Oberstein, Dafydd Thomas et al. · Cancer Cell · 2014 · 2K citations · Full text

Pancreatic Cancer, Surgical Pathology, Rather Than Support +6

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 467 citations

Nanotherapeutics, Pathology, Phase Ii Study +17

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 404 citations · Full text

Pancreatic cancer: why is it so hard to treat?

Paul E. Oberstein, Kenneth P. Olive · Therapeutic Advances in Gastroenterology · 2013 · 339 citations · Full text

Tumor Biology, Surgical Oncology, Pancreatic Cancer +11